Clinical trials: Cancer Refractory
MDS, AML, Adult
Quality of Life-Guided Transfusion in Refractory MDS or AML
Patients with refractory myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) in exclusive palliative care frequently receive red blood cell transfusions based on hemoglobin thresholds, despite limited evidence of…
- Conditions
- MDS, AML, Adult, Anemia
- Trial name
- Q-TRANS (NCT07328191)
- Testing
- Red blood cell transfusions based on EQ-5D-5L questionnaire
- Where
- France
- Volunteers
- 52 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Refractory Head and Neck Cancer, Squamous Cell Carcinoma, Skin
Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions
The purpose of this study is to determine whether HF10 is safe and effective in the treatment of head and neck cancer or solid tumors with cutaneous and/or superficial lesions.
- Conditions
- Refractory Head and Neck Cancer, Squamous Cell Carcinoma, Skin, Carcinoma of the Breast, Malignant Melanoma
- Trial name
- NCT01017185
- Testing
- HF10
- Where
- 5 sites in United States
- Volunteers
- 28 people
- Sponsor
- Takara Bio Inc.
Chronic Lymphocytic Leukemia
The Humanized Monoclonal Antibody Milatuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)
The purpose of this study is to determine whether Milatuzumab is effective in patients with refractory chronic lymphocytic leukemia, and also to find out in which range of doses is a response seen.
- Trial name
- NCT00868478
- Testing
- Milatuzumab
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- Kaplan Medical Center
Diffuse Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma
Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma
This phase Ib/II trial is aimed at studying the combination of a drug named Selinexor (selective inhibitor of nuclear export) in combination with standard therapy for B cell Non-Hodgkin's lymphoma called R-CHOP.
- Conditions
- Diffuse Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma, Recurrent Follicular Lymphoma
- Trial name
- NCT03147885
- Testing
- Selinexor
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Multiple Myeloma
A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma
This is a single-arm, open-label, dose-escalation study to evaluate the safety, tolerability, cellular kinetics and initial efficacy of CAR-T cell therapy targeting GPRC5D in multiple myeloma subjects who have failed the standard…
- Trial name
- NCT05016778
- Testing
- GPRC5D-CAR-T
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Zhejiang University
Acute Lymphocytic Leukemia
BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL
In this single-center, single-arm, prospective, Phase 1/2 study, the safety and efficacy of autologous BCOR and ZC3H12 genes knock-out CD19-targeting chimeric antigen receptor (CAR) T-cell therapy will be evaluated in patients…
- Trial name
- NCT07008885
- Testing
- CAR19TIF cells, Fludarabine, Cyclophosphamide
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Multiple Myeloma
Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma
To provide pomalidomide access to relapsed/refractory multiple myeloma subjects with a likelihood of benefit from the pomalidomide treatment while the medication is not commercially available
- Trial name
- PEXIUS (NCT01632826)
- Testing
- Pomalidomide
- Where
- 42 sites in United States, Canada
- Sponsor
- Celgene
Multiple Myeloma
A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody
Multiple myeloma (MM) is an incurable malignancy and accounts for 1 percentage (%) of all cancers and for 10% of all hematologic malignancies.
- Trial name
- NCT03525678
- Testing
- Belantamab mafodotin frozen liquid, Belantamab mafodotin lyophilized powder
- Where
- 59 sites in United States, Australia and 6 more
- Volunteers
- 221 people
- Sponsor
- GlaxoSmithKline
Acute Myeloid Leukemia, in Relapse, Recurrent Adult Acute Myeloid Leukemia
A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
This research study is studying a targeted therapy known as GO-203-2C as a possible treatment for with acute myeloid leukemia (AML) both alone and in combination with decitabine.
- Trial name
- NCT02204085
- Testing
- GO-203-2c, GO-203-2c + Decitabine
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Beth Israel Deaconess Medical Center
Solid Cancers
A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists
This is a single-arm, multicenter, Phase Ib study designed to describe the effect of GDC-0449 on the pharmacokinetics of rosiglitazone and oral contraceptives in patients with advanced solid tumors who are refractory to treatment…
- Trial name
- NCT01209143
- Testing
- Vismodegib, Rosiglitazone, Norethindrone/ethinyl estradiol
- Where
- 3 sites in United States
- Volunteers
- 52 people
- Sponsor
- Genentech, Inc.
NSCLC, Low Dose Radiotherapy
Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer
This phase I study aims to investigate the safety and efficacy of whole brain low dose radiotherapy (WB-LDRT) combined with ICI and intrathecal chemotherapy for treatment of refractory meningeal metastasis of lung cancer.
- Conditions
- NSCLC, Low Dose Radiotherapy, PD-1 Inhibitor, Leptomeningeal Metastasis
- Trial name
- NCT06431685
- Testing
- Whole Brain Low Dose Radiotherapy, Pemetrexed, Sintilimab
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Sichuan University
Central Nervous System Neoplasms, Pediatric Cancer
Pediatric Prospective Personalized Immune and Target Identification Trial
PPROSPERITIT is a prospective clinical study assessing the use of comprehensive molecular profiling to define the best matching targeted and immune treatment for relapsed, refractory or very high risk pediatric CNS tumors.
- Conditions
- Central Nervous System Neoplasms, Pediatric Cancer, GEN1 Gene Mutation, Tumor, Brain
- Trial name
- PPROSPERITIT (NCT04859543)
- Testing
- FoundationOneHeme
- Where
- 3 sites in Austria, Czechia
- Volunteers
- 80 people
- Sponsor
- Masaryk University
Refractory Metastatic Gastric Cancer
Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer
The purpose of this trial is to compare the effects of TAS-102 and best supportive care (BSC) with Placebo (an inactive drug) and best supportive care on metastatic gastric cancer.
- Trial name
- NCT02500043
- Testing
- TAS-102
- Where
- 139 sites in United States, Belarus and 16 more
- Volunteers
- 507 people
- Sponsor
- Taiho Oncology, Inc.
Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia
Sunitinib in Treating Patients With Idiopathic Myelofibrosis
This phase II trial is studying how well sunitinib works in treating patients with idiopathic myelofibrosis. Sunitinib may stop the growth of abnormal cells by blocking some of the enzymes needed for cell growth and by blocking…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT00387426
- Testing
- sunitinib malate
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
Sorafenib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Chemotherapy
RATIONALE: Sorafenib and erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of non-small cell lung cancer by blocking blood flow to the tumor.
- Trial name
- NCT00801385
- Testing
- erlotinib hydrochloride, sorafenib tosylate, DNA analysis
- Where
- South Korea
- Volunteers
- 47 people
- Sponsor
- Yonsei University
Relapsed/Refractory Acute Myeloid Leukemia
UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Main research purpose： Evaluate the safety and tolerance of UTAA06 injection in the treatment of patients with relapsed/refractory acute myeloid leukemia.
- Trial name
- NCT05731219
- Testing
- B7-H3 target, CAR gene modified gdT cell injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
This is an open-label, Phase I/Ib trial with a dose escalation phase, followed by a dose extension phase. The objective of the dose escalation phase is to evaluate the pharmacokinetics (PK) and MTD of P1446A-05 in…
- Trial name
- NCT02117336
- Testing
- P1446A-05
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Piramal Enterprises Limited
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
This phase Ib trial studies the effects of NKTR-255 in combination with chimeric antigen (CAR)-T cell therapy and to see how well they work in treating patients with large B-cell lymphoma that has come back (relapsed) or does not…
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, Recurrent Primary Mediastinal Large B-Cell Lymphoma
- Trial name
- NCT05359211
- Testing
- Cyclophosphamide, Fludarabine, Lisocabtagene Maraleucel
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Fred Hutchinson Cancer Center
Platinum-resistant or Refractory Ovarian Cancer
A Study of ABT-263 as Single Agent in Women With Platinum Resistant/Refractory Recurrent Ovarian Cancer
ABT-263 as single agent in women with platinum resistant/refractory recurrent ovarian cancer.
- Trial name
- MONAVI-1 (NCT02591095)
- Testing
- ABT-263
- Where
- 16 sites in France
- Volunteers
- 47 people
- Sponsor
- Centre Francois Baclesse
Multiple Myeloma
Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183)
The purpose of this study is to compare the efficacy of pomalidomide and low dose dexamethasone with pembrolizumab (MK-3475) to that of pomalidomide and low dose dexamethasone without pembrolizumab in terms of Progression-Free…
- Trial name
- NCT02576977
- Testing
- Pembrolizumab, Pomalidomide, Dexamethasone
- Volunteers
- 251 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.